001     182682
005     20240229145727.0
024 7 _ |a 10.1016/j.jbc.2022.102703
|2 doi
024 7 _ |a pmid:36395886
|2 pmid
024 7 _ |a 0021-9258
|2 ISSN
024 7 _ |a 1067-8816
|2 ISSN
024 7 _ |a 1083-351X
|2 ISSN
024 7 _ |a altmetric:138602178
|2 altmetric
037 _ _ |a DKFZ-2022-02850
041 _ _ |a English
082 _ _ |a 540
100 1 _ |a Hänle-Kreidler, Simon
|0 P:(DE-He78)d4c68225ca6cd393718be733a8e4097d
|b 0
|e First author
|u dkfz
245 _ _ |a The SCF-FBXW7 E3 ubiquitin ligase triggers degradation of Histone 3 Lysine 4 methyltransferase complex component WDR5 to prevent mitotic slippage.
260 _ _ |a Bethesda, Md.
|c 2022
|b Soc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1671705943_12658
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a ISSN 0021-9258 / #EA:F045#LA:F045#
520 _ _ |a During prolonged mitotic arrest induced by anti-microtubule drugs, cell fate decision is determined by two alternative pathways, one leading to cell death, the other inducing premature escape from mitosis by mitotic slippage. FBWX7, a member of the F-box family of proteins and substrate-targeting subunit of the SCF (SKP1-CUL1-F-Box) E3 ubiquitin ligase complex promotes mitotic cell death and prevents mitotic slippage, but molecular details underlying these roles for FBWX7 are unclear. In this study, we report that WDR5, a component of the mixed lineage leukemia (MLL) complex of Histone 3 Lysine 4 (H3K4) methyltransferases, is a substrate of FBXW7. We determined by co-immunoprecipitation experiments and in vitro binding assays that WDR5 interacts with FBXW7 in vivo and in vitro. SCF-FBXW7 mediates ubiquitination of WDR5 and targets it for proteasomal degradation. Furthermore, we find that WDR5 depletion counteracts FBXW7 loss-of-function by reducing mitotic slippage and polyploidization. In conclusion, our data elucidate a new mechanism in mitotic cell fate regulation which might contribute to prevent chemotherapy resistance in patients after anti-microtubule drug treatment.
536 _ _ |a 316 - Infektionen, Entzündung und Krebs (POF4-316)
|0 G:(DE-HGF)POF4-316
|c POF4-316
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a FBXW7
|2 Other
650 _ 7 |a WDR5
|2 Other
650 _ 7 |a chemoresistance
|2 Other
650 _ 7 |a mitotic slippage
|2 Other
650 _ 7 |a ubiquitylation (ubiquitination)
|2 Other
700 1 _ |a Richter, Kai
|0 P:(DE-He78)f08cb94a1ca44e0f65e828ea1c2edca4
|b 1
700 1 _ |a Hoffmann, Ingrid
|0 P:(DE-He78)b97fa0c782a162d952b6197f3b916379
|b 2
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.jbc.2022.102703
|g p. 102703 -
|0 PERI:(DE-600)1474604-9
|n 12
|p 102703
|t The journal of biological chemistry
|v 298
|y 2022
|x 0021-9258
909 C O |p VDB
|o oai:inrepo02.dkfz.de:182682
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)d4c68225ca6cd393718be733a8e4097d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)f08cb94a1ca44e0f65e828ea1c2edca4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)b97fa0c782a162d952b6197f3b916379
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-316
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Infektionen, Entzündung und Krebs
|x 0
914 1 _ |y 2022
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J BIOL CHEM : 2019
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-05-04
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-05-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-05-04
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2021-05-04
920 2 _ |0 I:(DE-He78)F045-20160331
|k F045
|l F045 Zellzykluskontrolle und Karzinogenese
|x 0
920 1 _ |0 I:(DE-He78)F045-20160331
|k F045
|l F045 Zellzykluskontrolle und Karzinogenese
|x 0
920 0 _ |0 I:(DE-He78)F045-20160331
|k F045
|l F045 Zellzykluskontrolle und Karzinogenese
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F045-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21